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Available online 28 September 2016Induced pluripotent stem cells (iPSCs) hold great promise to model diseases, where the disease affected cell type
is difﬁcult to access. Amajor obstacle for the development of diseasemodels is the lack of well characterized con-
trol iPSCs from old people not affected by such a disease. Furthermore, gene-editing approaches often require
iPSCs from healthy donors, where pathogenic mutations can be inserted if patient material is not available.
Here, we report the generation of an iPSC line (16423 #6) from a 77-year-old woman, who did not display any
disease symptoms at the time, when the skin biopsy was taken.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource table.Name of stem cell line hiPSC-16423 #6stitution Bioneer A/S
erson who created resource Natakarn Nimsanor, Ida Jørring, Bjørn Holst,
Benjamin Schmid
ontact person and email Benjamin Schmid, bsc@bioneer.dk
ate archived/stock date July 2016
rigin Human skin ﬁbroblasts
ype of resource Biological reagent: induced pluripotent stem cells
(iPSCs) derived from a 77-year-old healthy woman
ub-type Induced pluripotent stem cell
ey transcription factors Episomal plasmids containing hOCT4, hSOX2,
hL-MYC, hKLF4 and hLIN28 (Addgene plasmids
27,077, 27,078 and 27,080; Okita et al., 2011)uthentication Identity and purity of cell line conﬁrmed by
integration analysis, pluripotency analysis,
karyotyping and in vitro differentiation (Fig. 1).Resource details
Fibroblasts were obtained from a 77-year-old healthy woman, who
did not display any disease related symptoms. Reprogramming was. This is an open access article underperformed by electroporation with 3 episomal plasmids containing
hOCT4, hSOX2 and hKLF4, and hL-MYC and hLIN28 (Okita et al.,
2011). The line was termed hiPSC-16423 #6. qPCR analysis with plas-
mid-speciﬁc primers showed that none of the plasmids were present
anymore after reprogramming (Fig. 1A). qRT-PCR analysis showed
that the endogenous pluripotency genes OCT4, NANOG, GABRB3,
TDGF1 and DNMT38were expressed in the same range as in the control
iPSC line BIONi010-C iPSCs (Rasmussen et al., 2014) (Fig. 1B). Immuno-
cytochemistry (ICC) analysis demonstrated the presence of the
pluripotency markers OCT4, NANOG, TRA1-60, TRA1-81 and SSEA4 on
protein level (Fig. 1C). In vitro differentiation followed by ICC analysis
with themesodermalmarker smoothmuscle actin (SMA), the endoder-
malmarker alpha-1-fetoprotein (AFP) and the ectodermalmarker beta-
III-Tubulin (TUJI) demonstrated the differentiation potential into all
three germ layers (Fig. 1D). In addition, the iPSC-16423 #6 line main-




A skin biopsy was obtained from a 77-year-old healthy woman. Fi-
broblasts were cultured in ﬁbroblast medium, consisting of Dulbecco's
Modiﬁed Eagle Medium (DMEM, Life Technologies) supplemented
with 10% fetal bovine serum (FBS, Life Technologies), 2 mM L-gluta-
mine, and 1% penicillin and streptomycin. 1 × 105 ﬁbroblasts werethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) qPCR on genomic DNA from the 16423 #6 iPSC line and a pool of ﬁbroblasts 20 days after electroporation (positive control) with primers speciﬁc for each of the 3 plasmids.
Values were standardized relative to GAPDH. (C) qRT-PCR expression analyses of the endogenous pluripotency genes NANOG, OCT4, TDGF1, DNMT3B and GABRB3 on RNA from the
hiPSC-16423 #6 line and the iPSC line BIONi010-C as positive control. Data is shown as the fold expression change (2−ΔΔCt) to ﬁbroblasts. Values were standardized relative to
GAPDH. (D) Immunocytochemical staining of the stem cell markers OCT4, TRA1-81, NANOG, TRA1-60, SSEA3 and SSEA4 for the hiPSC-16423 #6 line. Scale bars correspond to 100 μm.
(E) Immunocytochemistry analysis for proteins representative of the three germ layers, Tuj1 (ectoderm), SMA (mesoderm) and AFP (endoderm), after in vitro differentiation by
embryoid body formation, scale bars = 200 μM. (F) Representative karyotype for the hiPSC-16423 #6 line (46, XX).
551N. Nimsanor et al. / Stem Cell Research 17 (2016) 550–552electroporated with a total of 1 μg of episomal plasmids containing
hOCT4 (Addgene plasmids 27076), hSOX2 and hKLF4 (Addgene plas-
mid 27078), and hL-MYC and hLIN28 (Addgene plasmid 27080; Okitaet al., 2011). Electroporation was carried out using a Neon™ electropo-
ration device with two pulses at 1200 V for 20 ms (Life Technologies).
After electroporation, the cells were cultured on ESC grade matrigel-
Table 1





Pluripotency Goat anti-OCT4 1:500 Santa Cruz, sc-8628
Rabbit anti-NANOG 1:100 Millipore, AB5731
Mouse anti-SSEA4 1:500 BioLegend, 330,402
Mouse anti TRA-1-60 1:500 BioLegend, 330,602
Mouse anti TRA-1-81 1:500 BioLegend, 330,702













552 N. Nimsanor et al. / Stem Cell Research 17 (2016) 550–552coated dishes (BDBiosciences) inﬁbroblastmedium. After 3–4 days, de-
pending on conﬂuency, the medium was changed to E8 medium con-
taining 100 μM NaB. Individual iPSC colonies were manually picked
and transferred to a new matrigel-coated dish. The iPSCs were split
once a week with 0.5 mM EDTA and frozen in liquid nitrogen in E8 me-
dium containing 10% DMSO and thawed in the presence of E8 medium
supplemented with 1:200 diluted Revita cell supplement (Gibco).
Integration analysis
DNA was puriﬁed from hiPSC-16423 #6 and a pool of ﬁbroblasts
electroporated with episomal plasmids and grown for 20 days as a pos-
itive control using the DNeasy Blood and Tissue kit (Qiagen). qPCR anal-
yses were carried out with the primers OCT4, SOX2, Lin28 and KLF4,
which are speciﬁc to the three plasmids (Okita et al., 2011), and data
was analyzed using the 2−ΔΔCt method standardized on GAPDHwith ﬁ-
broblasts as a reference.
qRT-PCR analysis of stem cell markers
Total RNA was puriﬁed from hiPSC-16423 #6, ﬁbroblasts and the
control iPSC line BIONi010-C using the RNeasy mini kit from Qiagen.
Conversion to cDNA was performed with RevertAid First Strand cDNA
synthesis kit (Thermo Scientiﬁc). qPCR analysis was carried out using
the TaqMan primers GAPDH Hs03929097_g1, NANOG Hs02387400_g1,
OCT4 Hs00999632_g1, TDGF1 Hs02339497_g1, DMNT3B
Hs00171876_m1 and GABRB3 Hs00241459_m1 (Thermo Scientiﬁc, In-
ternational Stem Cell Banking Initiative). Data was analyzed using the
2−ΔΔCt method standardized on GAPDHwith ﬁbroblasts as a reference.
Immunostaining of pluripotency markers
hiPSC-16423 #6 cells were seeded on matrigel coated coverslips.
After 2 days, the cells were ﬁxed at room temperature with 4% parafor-
maldehyde in PBS for 10min and permeabilized with 0.1% Triton X-100
and blockedwith 2% BSA in PBS for 1 h. Immunostainingwas performed
with primary antibodies against Oct4, Nanog, Tra-1-60, Tra-1-81, SSEA3
and SSEA4 (Table 1). After incubation with the primary antibody,
the cells were washed 3 times with PBS and then incubated withﬂuorescence-conjugated secondary antibodies Alexa ﬂuor 488 (goat
anti-mouse, 1:1000) or Cyanine 3 (goat anti-rabbit, 1:1000) for 1 h
(both Life technologies). The cells were coveredwithmounting solution
containing DAPI (Life Technologies) and transferred to an object plate.
In vitro differentiation
hiPSC-16423 #6were dissociatedwith EDTA (Gibco) and allowed to
form aggregates in none-coated cell culture dishes with E8medium. On
day 2, the E8 medium was changed to E6 medium (E6 medium = E8
medium without FGF2 and TGF-β1). On day 7, the aggregates were
transferred to matrigel-coated dishes and medium was switched to
differentiation medium. For mesodermal differentiation: DMEM/F12
containing 10% FBS, 1% L-glutamine, and 1% non-essential amino acids
(all Gibco). For endodermal differentiation: MCDB131–1 containing
0.5% BSA, 0.1% pen/strep, 3 μM CHIR99021 (Selleckchem), 100 ng/ml
Activin A (Cell Guidance). For ectodermal differentiation: DMEM/F12
mixed with neurobasal medium in a ratio of 1:1, 1× B27, 1× N2, and
1% L-glutamine (all Gibco), 10 μM SB 431542 and 0.1 μM LDN 193189
(both Selleckchem). Cells were ﬁxed for immunocytochemistry on day
21. ICC analysis was performed with the antibodies TUJI, SMA and AFP
(Table 1).
Karyotyping
hiPSC-16423 #6 were treated for 1 h with KaryoMAX colcemid
(Life Technologies) and harvested in fresh ﬁxative containing 25% acetic
acid and 75% methanol. Karyotyping was performed on G-banded
metaphase chromosomes using standard cytogenetic procedures. An
intact genome was demonstrated by karyotyping using G-banding of
15 mitoses. The analysis was performed at the Institute of Medical
Genetics and Applied Genomics, University of Tübingen, Germany. The
results showed a normal 46, XX karyotype, free of any discernible
abnormalities (Fig. 1F).
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